Experience with the Preparation of ⁶⁸Ga-PSMA-11

Authors

  • Michal Budinský Pharmacy, Masaryk Memorial Cancer Institute, Brno, Czech Republic | Department of Applied Pharmacy, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic
  • Petr Vyšinský Pharmacy, Masaryk Memorial Cancer Institute, Brno, Czech Republic
  • Zdeněk Řehák Department of Nuclear Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic
  • Jan Adam Department of Nuclear Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic | Division of Radiopharmaceuticals, ÚJV Řež, Husinec-Řež, Czech Republic

DOI:

https://doi.org/10.54779/chl20220746

Keywords:

⁶⁸Ga-PSMA-11, prostate cancer, radiopharmacy, nuclear medicine

Abstract

The radiopharmaceutical 68Ga-PSMA-11 represents a radiopharmaceutical drug without marketing authorization for the prostate cancer diagnosis in a specific treatment program. In respect of the radiopharmaceutical technology, the difficultness of the preparation of 68Ga-PSMA-11 is comparable to that of conventional radiopharmaceuticals.

Downloads

Published

2022-12-15

How to Cite

Budinský, M., Vyšinský, P., Řehák, Z., & Adam, J. (2022). Experience with the Preparation of ⁶⁸Ga-PSMA-11. Chemické Listy, 116(12), 746–750. https://doi.org/10.54779/chl20220746

Issue

Vol. 116 No. 12 (2022)

Section

Articles